Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H H Parving

Showing results (301-310 of 306) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 306 results.
Clinical Pharmacology and Therapeutics|September 27, 2013
The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockersP A Smink, Y Miao, M J C Eijkemans, et al.
Diabetologia|April 27, 2013
The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1M G A van Eupen, M T Schram, H M Colhoun, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 22, 2020
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-studyM Piazza, N M J Hanssen, F Persson, et al.
Diabetologia|August 17, 2010
A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitusA Alkhalaf, S J L Bakker, H J G Bilo, et al.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 23, 2002
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)B M Brenner, M E Cooper, D de Zeeuw, et al.
Pageof 31

Showing results (301-310 of 306) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 306 results.
Clinical Pharmacology and Therapeutics|September 27, 2013
The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockersP A Smink, Y Miao, M J C Eijkemans, et al.
Diabetologia|April 27, 2013
The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1M G A van Eupen, M T Schram, H M Colhoun, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 22, 2020
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-studyM Piazza, N M J Hanssen, F Persson, et al.
Diabetologia|August 17, 2010
A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitusA Alkhalaf, S J L Bakker, H J G Bilo, et al.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 23, 2002
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)B M Brenner, M E Cooper, D de Zeeuw, et al.
Pageof 31